S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:VINC

Vincerx Pharma (VINC) Stock Price, News & Analysis

$5.06
-1.00 (-16.50%)
(As of 03/28/2024 ET)
Today's Range
$4.95
$6.08
50-Day Range
$1.07
$8.06
52-Week Range
$0.61
$9.37
Volume
601,837 shs
Average Volume
1.09 million shs
Market Capitalization
$108.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Vincerx Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1.2% Downside
$5.00 Price Target
Short Interest
Bearish
6.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.84mentions of Vincerx Pharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.99) to ($0.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.85 out of 5 stars

Medical Sector

857th out of 938 stocks

Pharmaceutical Preparations Industry

386th out of 423 stocks

VINC stock logo

About Vincerx Pharma Stock (NASDAQ:VINC)

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

VINC Stock Price History

VINC Stock News Headlines

Vincerx Pharma Inc
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Vincerx Pharma Inc Ordinary Shares VINC
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Vincerx Pharma GAAP EPS of -$0.46
See More Headlines
Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VINC
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-1.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-65,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.25 per share

Miscellaneous

Free Float
16,977,000
Market Cap
$108.18 million
Optionable
Not Optionable
Beta
1.03
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives


VINC Stock Analysis - Frequently Asked Questions

Should I buy or sell Vincerx Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares.
View VINC analyst ratings
or view top-rated stocks.

What is Vincerx Pharma's stock price target for 2024?

1 Wall Street research analysts have issued 12 month price targets for Vincerx Pharma's stock. Their VINC share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests that the stock has a possible downside of 1.2%.
View analysts price targets for VINC
or view top-rated stocks among Wall Street analysts.

How have VINC shares performed in 2024?

Vincerx Pharma's stock was trading at $1.18 at the beginning of the year. Since then, VINC shares have increased by 328.8% and is now trading at $5.06.
View the best growth stocks for 2024 here
.

Are investors shorting Vincerx Pharma?

Vincerx Pharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 863,700 shares, an increase of 95.2% from the February 29th total of 442,400 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 6.4% of the company's shares are short sold.
View Vincerx Pharma's Short Interest
.

When is Vincerx Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VINC earnings forecast
.

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) released its quarterly earnings data on Thursday, August, 12th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.18.

Who are Vincerx Pharma's major shareholders?

Vincerx Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Goldman Sachs Group Inc. (8.00%), Goldman Sachs Group Inc. (8.00%) and Citadel Advisors LLC (0.92%). Insiders that own company stock include Ahmed Md Hamdy, Alexander A Seelenberger, Andrew I Mcdonald, Christopher P Lowe, Laura I Bushnell, Raquel E Izumi and Tom C Thomas.
View institutional ownership trends
.

How do I buy shares of Vincerx Pharma?

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VINC) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners